{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T01:29:18Z","timestamp":1786325358874,"version":"build-2736575974"},"reference-count":125,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.intimp.2026.117082","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T21:54:20Z","timestamp":1782856460000},"page":"117082","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Protein scaffold engineering for immune checkpoint targeting, tumor microenvironment modulation, and Cancer immunotherapy"],"prefix":"10.1016","volume":"186","author":[{"given":"Anuja","family":"Deshmukh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharav","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshdeep","family":"Pund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhuri","family":"kawade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2026.117082_bb0005","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2020.612950","article-title":"Implantable and injectable biomaterial scaffolds for Cancer immunotherapy","volume":"8","author":"Li","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"21","key":"10.1016\/j.intimp.2026.117082_bb0010","doi-asserted-by":"crossref","first-page":"6537","DOI":"10.3390\/jcm13216537","article-title":"Next-generation immunotherapy: advancing clinical applications in Cancer treatment","volume":"13","author":"Garg","year":"2024","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.intimp.2026.117082_bb0015","article-title":"Utilization of macrocyclic peptides to target protein-protein interactions in cancer","volume":"12","author":"Yang","year":"2022","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2026.117082_bb0020","first-page":"375","article-title":"Cancer immunotherapy: a promising dawn in cancer research","volume":"10","author":"Bondhopadhyay","year":"2020","journal-title":"Am. J. Blood Res."},{"issue":"8","key":"10.1016\/j.intimp.2026.117082_bb0025","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.3390\/pharmaceutics14081630","article-title":"Cancer immunotherapy and delivery system: an update","volume":"14","author":"Yang","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.intimp.2026.117082_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.818453","article-title":"Targeting Cancer cell ferroptosis to reverse immune checkpoint inhibitor therapy resistance","volume":"10","author":"Deng","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"issue":"11","key":"10.1016\/j.intimp.2026.117082_bb0035","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1002\/cac2.70064","article-title":"Mechanism and role of regulated cell death in tumor immunity and immunotherapy","volume":"45","author":"Hu","year":"2025","journal-title":"Cancer Commun."},{"issue":"1","key":"10.1016\/j.intimp.2026.117082_bb0040","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41392-024-01868-3","article-title":"Targeting cytokine and chemokine signaling pathways for cancer therapy","volume":"9","author":"Yi","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"3","key":"10.1016\/j.intimp.2026.117082_bb0045","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/1878-0261.13818","article-title":"Cytokine-centered strategies to boost cancer immunotherapy","volume":"19","author":"Manzano","year":"2025","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.intimp.2026.117082_bb0050","article-title":"Clinical cancer immunotherapy: current progress and prospects","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2026.117082_bb0055","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1039\/D2CB00094F","article-title":"Protein scaffolds: antibody alternatives for cancer diagnosis and therapy","volume":"3","author":"Luo","year":"2022","journal-title":"RSC Chem. Biol."},{"issue":"8","key":"10.1016\/j.intimp.2026.117082_bb0060","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.3390\/pharmaceutics14081630","article-title":"Cancer immunotherapy and delivery system: an update","volume":"14","author":"Yang","year":"2022","journal-title":"Pharmaceutics"},{"issue":"7910","key":"10.1016\/j.intimp.2026.117082_bb0065","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41586-022-04654-9","article-title":"Design of protein-binding proteins from the target structure alone","volume":"605","author":"Cao","year":"2022","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.intimp.2026.117082_bb0070","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s40643-023-00695-8","article-title":"Research progress of multi-enzyme complexes based on the design of scaffold protein","volume":"10","author":"Wang","year":"2023","journal-title":"Bioresour. Bioprocess."},{"key":"10.1016\/j.intimp.2026.117082_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.144881","article-title":"Transformative protein scaffold designs for dual-modality cancer applications: advances in therapeutic delivery and molecular imaging of tumor microenvironments","volume":"318","author":"Alissa","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.intimp.2026.117082_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.127946","article-title":"Study on the properties of a dual-system-based protein scaffold for orthogonal self-assembly","volume":"256","author":"Zhang","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"issue":"7","key":"10.1016\/j.intimp.2026.117082_bb0085","doi-asserted-by":"crossref","first-page":"878","DOI":"10.2174\/1389201021999200824101035","article-title":"Recent advances in the scaffold engineering of protein binders","volume":"22","author":"Ahmadi","year":"2021","journal-title":"Curr. Pharm. Biotechnol."},{"issue":"10","key":"10.1016\/j.intimp.2026.117082_bb0090","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.3390\/biom13101508","article-title":"Development of an anti-HER2 single-chain variable antibody fragment construct for high-yield soluble expression in Escherichia coli and one-step chromatographic purification","volume":"13","author":"Byun","year":"2023","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.intimp.2026.117082_bb0095","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1146\/annurev-pharmtox-010818-021118","article-title":"Engineered protein scaffolds as next-generation therapeutics","volume":"60","author":"Gebauer","year":"2020","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.intimp.2026.117082_bb0100","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.copbio.2019.05.007","article-title":"Engineering of binding functions into proteins","volume":"60","author":"Gebauer","year":"2019","journal-title":"Curr. Opin. Biotechnol."},{"issue":"4","key":"10.1016\/j.intimp.2026.117082_bb0105","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1021\/acscombsci.8b00182","article-title":"Biophysical characterization platform informs protein scaffold evolvability","volume":"21","author":"Golinski","year":"2019","journal-title":"ACS Comb. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2026.117082_bb0110","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.xphs.2019.08.009","article-title":"Physicochemical stability of monoclonal antibodies: a review","volume":"109","author":"Le Basle","year":"2020","journal-title":"J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.intimp.2026.117082_bb0115","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3390\/microorganisms6040097","article-title":"Thermophilic proteins as versatile scaffolds for protein engineering","volume":"6","author":"Finch","year":"2018","journal-title":"Microorganisms"},{"issue":"6","key":"10.1016\/j.intimp.2026.117082_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12060551","article-title":"Evaluating the therapeutic efficacy of mono- and bivalent affibody-based fusion proteins targeting HER3 in a pancreatic cancer xenograft model","volume":"12","author":"Dahlsson Leitao","year":"2020","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.intimp.2026.117082_bb0125","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/separations8010004","article-title":"Analysis of monoclonal antibodies by capillary electrophoresis: sample preparation, separation, and detection","volume":"8","author":"Dadouch","year":"2021","journal-title":"Separations"},{"issue":"2","key":"10.1016\/j.intimp.2026.117082_bb0130","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/abt\/tbae005","article-title":"Reforming solid tumor treatment: the emerging potential of smaller format antibody-drug conjugate","volume":"7","author":"Ma","year":"2024","journal-title":"Antibody Therapeutics"},{"key":"10.1016\/j.intimp.2026.117082_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.btre.2021.e00670","article-title":"Protein scaffolds: a tool for multi-enzyme assembly","volume":"32","author":"Gad","year":"2021","journal-title":"Biotechnology Reports"},{"issue":"10","key":"10.1016\/j.intimp.2026.117082_bb0140","doi-asserted-by":"crossref","first-page":"8680","DOI":"10.3390\/ijms24108680","article-title":"Recent advances on affibody- and DARPin-conjugated nanomaterials in Cancer therapy","volume":"24","author":"Gabriele","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.intimp.2026.117082_bb0145","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s10529-022-03276-5","article-title":"Current trends in biopharmaceuticals production in Escherichia coli","volume":"44","author":"McElwain","year":"2022","journal-title":"Biotechnol. Lett."},{"issue":"24","key":"10.1016\/j.intimp.2026.117082_bb0150","doi-asserted-by":"crossref","first-page":"16000","DOI":"10.1021\/acsomega.1c01811","article-title":"Comparative evaluation of engineered polypeptide scaffolds in HER2-targeting magnetic nanocarrier delivery","volume":"6","author":"Shipunova","year":"2021","journal-title":"ACS Omega"},{"issue":"2","key":"10.1016\/j.intimp.2026.117082_bb0155","first-page":"114","article-title":"Reforming solid tumor treatment: the emerging potential of smaller format antibody-drug conjugate","volume":"7","author":"Ma","year":"2024","journal-title":"Antib. Ther."},{"issue":"6","key":"10.1016\/j.intimp.2026.117082_bb0160","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12060551","article-title":"Evaluating the therapeutic efficacy of mono- and bivalent affibody-based fusion proteins targeting HER3 in a pancreatic cancer xenograft model","volume":"12","author":"Dahlsson Leitao","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.intimp.2026.117082_bb0165","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.freeradbiomed.2022.02.031","article-title":"Nanobodies as molecular imaging probes","volume":"182","author":"Barakat","year":"2022","journal-title":"Free Radic. Biol. Med."},{"issue":"2","key":"10.1016\/j.intimp.2026.117082_bb0170","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3390\/ijms18020401","article-title":"A conjugate based on anti-HER2 Diaffibody and auristatin E targets HER2-positive Cancer cells","volume":"18","author":"Serwotka-Suszczak","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2026.117082_bb0175","series-title":"Advances in the Application of Designed Ankyrin Repeat Proteins (DARPins) as Research Tools and Protein Therapeutics","author":"Boersma","year":"2018"},{"issue":"10","key":"10.1016\/j.intimp.2026.117082_bb0180","doi-asserted-by":"crossref","first-page":"7323","DOI":"10.1007\/s11033-020-05752-5","article-title":"DARPin Ec1-LMWP protein scaffold in targeted delivery of siRNA molecules through EpCAM cancer stem cell marker","volume":"47","author":"Babaee","year":"2020","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.intimp.2026.117082_bb0185","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.ijbiomac.2017.04.045","article-title":"Recent advances in the development of novel protein scaffolds based therapeutics","volume":"102","author":"Azhar","year":"2017","journal-title":"Int. J. Biol. Macromol."},{"issue":"19","key":"10.1016\/j.intimp.2026.117082_bb0190","doi-asserted-by":"crossref","first-page":"5878","DOI":"10.1158\/1078-0432.CCR-18-3654","article-title":"Tumor-localized costimulatory T-cell engagement by the 4-1BB\/HER2 bispecific antibody-anticalin fusion PRS-343","volume":"25","author":"Hinner","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.intimp.2026.117082_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3126\/ajms.v14i10.58169","article-title":"Monobodies and nanobodies: the era of diagnostic miniature antibodies","volume":"14","author":"Dhar","year":"2023","journal-title":"Asian J. Med. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2026.117082_bb0200","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-024-06569-9","article-title":"Ubiquitin-derived artificial binding proteins targeting oncofetal fibronectin reveal scaffold plasticity by \u03b2-strand slippage","volume":"7","author":"Katzschmann","year":"2024","journal-title":"Commun. Biol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117082_bb0205","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1038\/s41598-019-39776-0","article-title":"Enhancing bioactivity, physicochemical, and pharmacokinetic properties of a nano-sized, anti-VEGFR2 Adnectin, through PASylation technology","volume":"9","author":"Aghaabdollahian","year":"2019","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.intimp.2026.117082_bb0210","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.3390\/ijms25073737","article-title":"Identification of inhibitors of the disease-associated protein phosphatase Scp1 using antibody mimetic molecules","volume":"25","author":"Kobayashi","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"D1","key":"10.1016\/j.intimp.2026.117082_bb0215","doi-asserted-by":"crossref","first-page":"D454","DOI":"10.1093\/nar\/gkx1084","article-title":"KNOTTIN: the database of inhibitor cystine knot scaffold after 10 years, toward a systematic structure modeling","volume":"46","author":"Postic","year":"2018","journal-title":"Nucleic Acids Res."},{"issue":"9","key":"10.1016\/j.intimp.2026.117082_bb0220","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3390\/cancers9090110","article-title":"Integrins as therapeutic targets: successes and cancers","volume":"9","author":"Raab-Westphal","year":"2017","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2026.117082_bb0225","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1215939","article-title":"Does human homology reduce the potential immunogenicity of non-antibody scaffolds?","volume":"14","author":"De Groot","year":"2023","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2026.117082_bb0230","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1134\/S0006297923090043","article-title":"Non-immunoglobulin synthetic binding proteins for oncology","volume":"88","author":"David","year":"2023","journal-title":"Biochem. Mosc."},{"issue":"1","key":"10.1016\/j.intimp.2026.117082_bb0235","doi-asserted-by":"crossref","DOI":"10.3390\/toxins11010053","article-title":"Toxin neutralization using alternative binding proteins","volume":"11","author":"Jenkins","year":"2019","journal-title":"Toxins"},{"issue":"10","key":"10.1016\/j.intimp.2026.117082_bb0240","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41573-022-00501-8","article-title":"Avidity in antibody effector functions and biotherapeutic drug design","volume":"21","author":"Oostindie","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"11","key":"10.1016\/j.intimp.2026.117082_bb0245","doi-asserted-by":"crossref","DOI":"10.3390\/ph18111669","article-title":"Recent progress on affibody-based supramolecular architectures: moving from monomeric constructs to multivalent assemblies","volume":"18","author":"Wang","year":"2025","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.intimp.2026.117082_bb0250","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1186\/s12951-025-03631-4","article-title":"Engineering bispecific HER2xVEGF designed ankyrin repeat proteins for targeted nanobiotechnology applications","volume":"23","author":"Chen","year":"2025","journal-title":"J. Nanobiotechnology"},{"issue":"12","key":"10.1016\/j.intimp.2026.117082_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.113926","article-title":"Development of DARPin T cell engagers for specific targeting of tumor-associated HLA\/peptide complexes","volume":"28","author":"Venetz-Arenas","year":"2025","journal-title":"iScience"},{"issue":"12","key":"10.1016\/j.intimp.2026.117082_bb0260","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15123149","article-title":"Direct intra-patient comparison of scaffold protein-based tracers, [99mTc]Tc-ADAPT6 and [99mTc]Tc-(HE)3-G3, for imaging of HER2-positive breast cancer","volume":"15","author":"Bragina","year":"2023","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.intimp.2026.117082_bb0265","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1080\/14712598.2021.1839046","article-title":"Anticalin\u00ae proteins: from bench to bedside","volume":"21","author":"Deuschle","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"issue":"9","key":"10.1016\/j.intimp.2026.117082_bb0270","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1134\/S0006297923090043","article-title":"Non-immunoglobulin synthetic binding proteins for oncology","volume":"88","author":"David","year":"2023","journal-title":"Biochemistry (Moscow)"},{"issue":"3","key":"10.1016\/j.intimp.2026.117082_bb0275","doi-asserted-by":"crossref","first-page":"610","DOI":"10.3390\/cells9030610","article-title":"Development and differentiation in Monobodies based on the fibronectin type 3 domain","volume":"9","author":"Chandler","year":"2020","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.intimp.2026.117082_bb0280","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3390\/biom11121791","article-title":"Non-antibody-based binders for the enrichment of proteins for analysis by mass spectrometry","volume":"11","author":"Olaleye","year":"2021","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.intimp.2026.117082_bb0285","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s13238-017-0386-6","article-title":"In vitro-engineered non-antibody protein therapeutics","volume":"9","author":"Simeon","year":"2018","journal-title":"Protein Cell"},{"issue":"3","key":"10.1016\/j.intimp.2026.117082_bb0290","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.cell.2023.12.028","article-title":"De novo protein design\u2014from new structures to programmable functions","volume":"187","author":"Kortemme","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2026.117082_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2022.108032","article-title":"Protein scaffolds in human clinics","volume":"61","author":"Cano-Garrido","year":"2022","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.intimp.2026.117082_bb0300","article-title":"Protein scaffolds: building blocks for next-generation therapeutics-a review","volume":"120","author":"Penemecha","year":"2026","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"20","key":"10.1016\/j.intimp.2026.117082_bb0305","doi-asserted-by":"crossref","first-page":"11314","DOI":"10.1021\/acs.jcim.5c01708","article-title":"De N ovo -designed Miniprotein inhibits the enzymatic activity of the SARS-CoV-2 Main protease","volume":"65","author":"Lima","year":"2025","journal-title":"J. Chem. Inf. Model."},{"issue":"4","key":"10.1016\/j.intimp.2026.117082_bb0310","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.tibs.2019.12.008","article-title":"Miniproteins as a powerful modality in drug development","volume":"45","author":"Crook","year":"2020","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.intimp.2026.117082_bb0315","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ijbiomac.2016.10.045","article-title":"Important amino acid residues involved in folding and binding of protein\u2013protein complexes","volume":"94","author":"Kulandaisamy","year":"2017","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.intimp.2026.117082_bb0320","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cbpa.2018.05.013","article-title":"Engineered protein scaffolds as leads for synthetic inhibitors of protein\u2013protein interactions","volume":"44","author":"Wuo","year":"2018","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"17","key":"10.1016\/j.intimp.2026.117082_bb0325","doi-asserted-by":"crossref","DOI":"10.1002\/jcc.70160","article-title":"Evaluation of physics-based protein design methods for predicting single residue effects on peptide binding specificities","volume":"46","author":"Ayyildiz","year":"2025","journal-title":"J. Comput. Chem."},{"issue":"21","key":"10.1016\/j.intimp.2026.117082_bb0330","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111788","article-title":"Surface engineering strategies to enhance the in situ performance of medical devices including atomic scale engineering","volume":"22","author":"Sultana","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2026.117082_bb0335","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.pbiomolbio.2025.07.003","article-title":"Computational protein design: advancing biotechnology through in silico engineering","volume":"197","author":"Ranbhor","year":"2025","journal-title":"Prog. Biophys. Mol. Biol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117082_bb0340","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/ird3.11","article-title":"High-throughput screening and biological display technology: applications in molecular imaging","volume":"1","author":"Luo","year":"2023","journal-title":"iRADIOLOGY"},{"issue":"2","key":"10.1016\/j.intimp.2026.117082_bb0345","doi-asserted-by":"crossref","DOI":"10.1093\/femsre\/fuab052","article-title":"Phage display and other peptide display technologies","volume":"46","author":"Jaroszewicz","year":"2022","journal-title":"FEMS Microbiol. Rev."},{"key":"10.1016\/j.intimp.2026.117082_bb0350","article-title":"Engineered M13 phage as a novel therapeutic bionanomaterial for clinical applications: from tissue regeneration to cancer therapy","volume":"20","author":"Chang","year":"2023","journal-title":"Mater. Today Bio"},{"issue":"1","key":"10.1016\/j.intimp.2026.117082_bb0355","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12934-018-0881-3","article-title":"Beyond antibody engineering: directed evolution of alternative binding scaffolds and enzymes using yeast surface display","volume":"17","author":"K\u00f6nning","year":"2018","journal-title":"Microb. Cell Fact."},{"key":"10.1016\/j.intimp.2026.117082_bb0360","series-title":"Protein Engineering and Selection Using Yeast Surface Display","first-page":"3","author":"Angelini","year":"2015"},{"issue":"3","key":"10.1016\/j.intimp.2026.117082_bb0365","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/antib9030028","article-title":"Ribosome display technology: applications in disease diagnosis and control","volume":"9","author":"Kunamneni","year":"2020","journal-title":"Antibodies"},{"issue":"5","key":"10.1016\/j.intimp.2026.117082_bb0370","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.tibs.2022.01.001","article-title":"Methods for the directed evolution of biomolecular interactions","volume":"47","author":"Xie","year":"2022","journal-title":"Trends Biochem. Sci."},{"issue":"8","key":"10.1016\/j.intimp.2026.117082_bb0375","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41592-019-0496-6","article-title":"Machine-learning-guided directed evolution for protein engineering","volume":"16","author":"Yang","year":"2019","journal-title":"Nat. Methods"},{"issue":"8","key":"10.1016\/j.intimp.2026.117082_bb0380","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/s41589-024-01642-0","article-title":"Rationally seeded computational protein design of \u03b1-helical barrels","volume":"20","author":"Albanese","year":"2024","journal-title":"Nat. Chem. Biol."},{"issue":"W1","key":"10.1016\/j.intimp.2026.117082_bb0385","doi-asserted-by":"crossref","first-page":"W272","DOI":"10.1093\/nar\/gkae384","article-title":"PROSCA: an online platform for humanized scaffold mining facilitating rational protein engineering","volume":"52","author":"Wang","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.intimp.2026.117082_bb0390","series-title":"Protein and Antibody Engineering by Phage Display","first-page":"45","author":"Frei","year":"2016"},{"issue":"2","key":"10.1016\/j.intimp.2026.117082_bb0395","doi-asserted-by":"crossref","DOI":"10.1093\/femsre\/fuab052","article-title":"Phage display and other peptide display technologies","volume":"46","author":"Jaroszewicz","year":"2022","journal-title":"FEMS Microbiol. Rev."},{"issue":"9","key":"10.1016\/j.intimp.2026.117082_bb0400","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1021\/acs.chemrev.4c00004","article-title":"Diversification of phage-displayed peptide libraries with noncanonical amino acid mutagenesis and chemical modification","volume":"124","author":"Hampton","year":"2024","journal-title":"Chem. Rev."},{"issue":"4","key":"10.1016\/j.intimp.2026.117082_bb0405","doi-asserted-by":"crossref","DOI":"10.3390\/bioengineering11040381","article-title":"Development of a human B7-H3-specific antibody with activity against colorectal cancer cells through a synthetic nanobody library","volume":"11","author":"Li","year":"2024","journal-title":"Bioengineering"},{"issue":"2","key":"10.1016\/j.intimp.2026.117082_bb0410","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.abb.2012.04.022","article-title":"Directed evolution of proteins for increased stability and expression using yeast display","volume":"526","author":"Traxlmayr","year":"2012","journal-title":"Arch. Biochem. Biophys."},{"issue":"2","key":"10.1016\/j.intimp.2026.117082_bb0415","article-title":"Strategies to screen anti-AQP4 antibodies from yeast surface display libraries","volume":"11","author":"Huang","year":"2022","journal-title":"Antibodies (Basel, Switzerland)"},{"key":"10.1016\/j.intimp.2026.117082_bb0420","series-title":"Cell-Free Display Techniques for Protein Evolution","first-page":"59","author":"Li","year":"2023"},{"issue":"1","key":"10.1016\/j.intimp.2026.117082_bb0425","article-title":"Development of uniform ribosome display technology enabling easy and efficient identification of full-length proteins that interact with bioactive small and large molecules","volume":"26","author":"Taguchi","year":"2025","journal-title":"ChemBioChem"},{"issue":"3","key":"10.1016\/j.intimp.2026.117082_bb0430","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.3390\/ijms25031798","article-title":"Virtual screening of peptide libraries: the search for peptide-based therapeutics using computational tools","volume":"25","author":"Vincenzi","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.intimp.2026.117082_bb0435","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1134\/S0026893323020218","article-title":"Modern approaches to protein engineering to create enzymes with new catalytic properties","volume":"57","author":"Tyugashev","year":"2023","journal-title":"Mol. Biol."},{"issue":"41","key":"10.1016\/j.intimp.2026.117082_bb0440","doi-asserted-by":"crossref","first-page":"4932","DOI":"10.2174\/1381612825666190206105232","article-title":"Recent advances in half-life extension strategies for therapeutic peptides and proteins","volume":"24","author":"Tan","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.intimp.2026.117082_bb0445","series-title":"Engineering of Biomaterials for Drug Delivery Systems","first-page":"27","article-title":"The case for protein PEGylation","author":"Awwad","year":"2018"},{"key":"10.1016\/j.intimp.2026.117082_bb0450","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jconrel.2018.07.023","article-title":"Cellular recycling-driven in vivo half-life extension using recombinant albumin fusions tuned for neonatal fc receptor (FcRn) engagement","volume":"287","author":"Larsen","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.intimp.2026.117082_bb0455","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jbiotec.2017.05.017","article-title":"Albumin-binding domain from Streptococcus zooepidemicus protein Zag as a novel strategy to improve the half-life of therapeutic proteins","volume":"253","author":"Cantante","year":"2017","journal-title":"J. Biotechnol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117082_bb0460","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/jssc.202000765","article-title":"Therapeutic fc-fusion proteins: current analytical strategies","volume":"44","author":"Duivelshof","year":"2021","journal-title":"J. Sep. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2026.117082_bb0465","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/14712598.2024.2436094","article-title":"Strategies for extending the half-life of biotherapeutics: successes and complications","volume":"25","author":"Binder","year":"2025","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.intimp.2026.117082_bb0470","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2019.4814","article-title":"Potent and specific fusion toxins consisting of a HER2-binding, ABD-derived affinity protein, fused to truncated versions of Pseudomonas exotoxin a","author":"Liu","year":"2019","journal-title":"Int. J. Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2026.117082_bb0475","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00281-022-00966-0","article-title":"Tumor microenvironment antigens","volume":"45","author":"Andersen","year":"2023","journal-title":"Semin. Immunopathol."},{"issue":"5","key":"10.1016\/j.intimp.2026.117082_bb0480","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s43018-021-00210-y","article-title":"Targeting public neoantigens for cancer immunotherapy","volume":"2","author":"Pearlman","year":"2021","journal-title":"Nat. Cancer"},{"issue":"7","key":"10.1016\/j.intimp.2026.117082_bb0485","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/s41587-022-01567-w","article-title":"Facile repurposing of peptide\u2013MHC-restricted antibodies for cancer immunotherapy","volume":"41","author":"Yang","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.intimp.2026.117082_bb0490","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1027548","article-title":"TCR mimic compounds for pHLA targeting with high potency modalities in oncology","volume":"12","author":"Gerber","year":"2022","journal-title":"Front. Oncol."},{"issue":"12","key":"10.1016\/j.intimp.2026.117082_bb0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.113926","article-title":"Development of DARPin T cell engagers for specific targeting of tumor-associated HLA\/peptide complexes","volume":"28","author":"Venetz-Arenas","year":"2025","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.intimp.2026.117082_bb0500","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-32811-1","article-title":"Therapeutic high affinity T cell receptor targeting a KRASG12D cancer neoantigen","volume":"13","author":"Poole","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.intimp.2026.117082_bb0505","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2253788","article-title":"Biophysical characterization of PVR family interactions and therapeutic antibody recognition to TIGIT","volume":"15","author":"Diong","year":"2023","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.intimp.2026.117082_bb0510","article-title":"Predictive biomarkers and mechanisms underlying resistance to PD1\/PD-L1 blockade cancer immunotherapy","volume":"19","author":"Ren","year":"2020","journal-title":"Mol. Cancer"},{"issue":"11","key":"10.1016\/j.intimp.2026.117082_bb0515","doi-asserted-by":"crossref","first-page":"8531","DOI":"10.1021\/acsnano.4c01597","article-title":"Engineering a programmed death-ligand 1-targeting Monobody via directed evolution for SynNotch-gated cell therapy","volume":"18","author":"Zhu","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.intimp.2026.117082_bb0520","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jconrel.2018.08.040","article-title":"Affibody-derived drug conjugates: potent cytotoxic molecules for treatment of HER2 over-expressing tumors","volume":"288","author":"Altai","year":"2018","journal-title":"J. Control. Release"},{"issue":"12","key":"10.1016\/j.intimp.2026.117082_bb0525","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241210126","article-title":"Novel bifunctional affibody molecules with specific binding to both EBV LMP1 and LMP2 for targeted therapy of nasopharyngeal carcinoma","volume":"24","author":"Kamara","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2026.117082_bb0530","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-10419-2","article-title":"KRAS-specific inhibition using a DARPin binding to a site in the allosteric lobe","volume":"10","author":"Bery","year":"2019","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.intimp.2026.117082_bb0535","doi-asserted-by":"crossref","first-page":"626","DOI":"10.4103\/1735-5362.389950","article-title":"Computational design of newly engineered DARPins as HER2 receptor inhibitors for breast cancer treatment","volume":"18","author":"Isfahani","year":"2023","journal-title":"Res. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2026.117082_bb0540","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/7375947","article-title":"Profound functional suppression of tumor-infiltrating T-cells in ovarian cancer patients can be reversed using PD-1-blocking antibodies or DARPin\u00ae proteins","volume":"2020","author":"Foord","year":"2020","journal-title":"J. Immunol. Res."},{"issue":"37","key":"10.1016\/j.intimp.2026.117082_bb0545","doi-asserted-by":"crossref","first-page":"14924","DOI":"10.1073\/pnas.1303640110","article-title":"Dissection of the BCR-ABL signaling network using highly specific monobody inhibitors to the SHP2 SH2 domains","volume":"110","author":"Sha","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"8","key":"10.1016\/j.intimp.2026.117082_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2023.168010","article-title":"Monobody inhibitor selective to the phosphatase domain of SHP2 and its use as a probe for quantifying SHP2 allosteric regulation","volume":"435","author":"Sha","year":"2023","journal-title":"J. Mol. Biol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117082_bb0555","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41392-024-01934-w","article-title":"The JAK-STAT pathway: from structural biology to cytokine engineering","volume":"9","author":"Lv","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"3","key":"10.1016\/j.intimp.2026.117082_bb0560","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s40259-018-0278-1","article-title":"Anticalin\u00ae proteins as therapeutic agents in human diseases","volume":"32","author":"Rothe","year":"2018","journal-title":"BioDrugs"},{"issue":"10","key":"10.1016\/j.intimp.2026.117082_bb0565","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1016\/j.apsb.2023.05.035","article-title":"Small molecules targeting protein\u2013protein interactions for cancer therapy","volume":"13","author":"Wu","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"19","key":"10.1016\/j.intimp.2026.117082_bb0570","doi-asserted-by":"crossref","DOI":"10.1002\/ange.202200951","article-title":"Cystine knot peptides with tuneable activity and mechanism","volume":"134","author":"Li","year":"2022","journal-title":"Angew. Chem."},{"issue":"5","key":"10.1016\/j.intimp.2026.117082_bb0575","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/jha2.968","volume":"5","author":"Knop","year":"2024","journal-title":"EJHaem"},{"issue":"2","key":"10.1016\/j.intimp.2026.117082_bb0580","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.20.00596","article-title":"First-in-human phase I study of MP0250, a first-in-class DARPin drug candidate targeting VEGF and HGF, in patients with advanced solid Tumors","volume":"39","author":"Baird","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.117082_bb0585","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1215939","article-title":"Does human homology reduce the potential immunogenicity of non-antibody scaffolds?","volume":"14","author":"De Groot","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117082_bb0590","doi-asserted-by":"crossref","first-page":"14188","DOI":"10.1038\/s41598-023-41525-3","article-title":"Design of an alternate antibody fragment format that can be produced in the cytoplasm of Escherichia coli","volume":"13","author":"Tungekar","year":"2023","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2026.117082_bb0595","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s13238-017-0386-6","article-title":"In vitro-engineered non-antibody protein therapeutics","volume":"9","author":"Simeon","year":"2018","journal-title":"Protein Cell"},{"issue":"13","key":"10.1016\/j.intimp.2026.117082_bb0600","doi-asserted-by":"crossref","DOI":"10.1093\/femsle\/fny138","article-title":"Scale-up of industrial microbial processes","volume":"365","author":"Crater","year":"2018","journal-title":"FEMS Microbiol. Lett."},{"issue":"3","key":"10.1016\/j.intimp.2026.117082_bb0605","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/ijtm5030028","article-title":"Protein engineering paving the way for next-generation therapies in Cancer","volume":"5","author":"Naderiyan","year":"2025","journal-title":"International Journal of Translational Medicine"},{"key":"10.1016\/j.intimp.2026.117082_bb0610","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01301","article-title":"T-cell dependent immunogenicity of protein therapeutics pre-clinical assessment and mitigation\u2013updated consensus and review 2020","volume":"11","author":"Jawa","year":"2020","journal-title":"Front. Immunol."},{"issue":"7976","key":"10.1016\/j.intimp.2026.117082_bb0615","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41586-023-06415-8","article-title":"De novo design of protein structure and function with RFdiffusion","volume":"620","author":"Watson","year":"2023","journal-title":"Nature"},{"issue":"49","key":"10.1016\/j.intimp.2026.117082_bb0620","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2307371120","article-title":"In silico evolution of autoinhibitory domains for a PD-L1 antagonist using deep learning models","volume":"120","author":"Goudy","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"8016","key":"10.1016\/j.intimp.2026.117082_bb0625","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926009288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926009288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:54:53Z","timestamp":1786323293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926009288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":125,"alternative-id":["S1567576926009288"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117082","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protein scaffold engineering for immune checkpoint targeting, tumor microenvironment modulation, and Cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117082","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117082"}}